4.5 Article

Dietary selenium and major depression: a nested case-control study

Journal

COMPLEMENTARY THERAPIES IN MEDICINE
Volume 20, Issue 3, Pages 119-123

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.ctim.2011.12.008

Keywords

Antioxidant; Diet; Epidemiology; Major depressive disorder; Dietary selenium; Risk factor; Women

Funding

  1. Victorian Health Promotion Foundation
  2. NHMRC [628912, 1012472]
  3. Stanley Medical Research Foundation
  4. MBF
  5. Beyond Blue
  6. Geelong Medical Research Foundation
  7. Bristol Myers Squibb
  8. Eli Lilly
  9. Glaxo SmithKline
  10. Organon
  11. Novartis
  12. Mayne Pharma
  13. Servier
  14. Astra Zeneca
  15. NHMRC (Australia)

Ask authors/readers for more resources

Objectives and methods: Alterations in redox biology are established in depression; however, there are no prospective epidemiological data on redox-active selenium in depression. We aimed to determine if low levels of dietary selenium are associated with an increased risk for de novo major depressive disorder (MDD). In this nested case-control study, women aged 20 years or more were identified from a randomly selected cohort being followed prospectively for the Geelong Osteoporosis Study. Cases were individuals with incident MDD, identified using the Structured Clinical Interview for DSM-IV-TR (SCID-I/NP); controls had no such history. Dietary selenium intake was measured using a food frequency questionnaire at baseline, together with anthropometric and lifestyle measures. Results: Eighteen women who developed de nova MDD were classified as cases; there were 298 controls. Low dietary selenium intakes increased the likelihood of developing MDD; OR 2.74 (95%CI 0.95-7.89). After adjusting for age and SES, compared with a high selenium intake, a low intake (<8.9 mu g/MJ/day) was associated with an approximate trebling of the likelihood for developing de novo MDD; OR 2.95 (95%CI 1.00-8.72). Smoking, alcohol consumption and physical activity did not confound the association. Conclusion: These data suggest that lower dietary selenium intakes are associated with an increased risk of subsequent de novo MDD. We propose that selenium's function as an antioxidant, and as a constituent of selenoproteins that are important in redox homeostasis, warrants further investigation as a risk factor for depression, and suggest a potentially novel modifiable factor in the primary prevention and management of depression. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available